Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 8/20 | 0.54 |
| ▸ | CDK2 | P24941 | 8/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230705 | 0.87 | CDK2 (0.52) | CCNA2CDK2CCNA1SCN9ATRPV1 | |
| SCHEMBL5228375 | 0.86 | CCNA2 (0.56) | CCNA2CDK2CCNA1SCN9A | |
| SCHEMBL5225569 | 0.85 | CCNA2 (0.52) | CCNA2CDK2CCNA1RIPK2 | |
| SCHEMBL5230469 | 0.85 | CDK2 (0.52) | CCNA2CDK2CCNA1TRPV1 | |
| SCHEMBL5227808 | 0.85 | CCNA2 (0.43) | CCNA2CDK2CCNA1SCN9ARIPK2 | |
| SCHEMBL5229177 | 0.84 | CCNA2 (0.50) | CCNA2CDK2CCNA1SCN9ARIPK2 | |
| SCHEMBL5230050 | 0.84 | CCNA2 (0.42) | CCNA2CDK2CCNA1SCN9ASMN1; SMN2 | |
| SCHEMBL5225453 | 0.82 | CCNA2 (0.54) | CCNA2CDK2CCNA1SCN9ARIPK2 | |
| SCHEMBL5227507 | 0.82 | CDK2 (0.54) | CCNA2CDK2CCNA1 | |
| SCHEMBL5228781 | 0.82 | CCNA2 (0.54) | CCNA2CDK2CCNA1SCN9ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | claimed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | claimed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-02-10 | — | — | US | disclosed |
| EP-1478357-B1 | TRICYCLIC PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-01-31 | — | — | EP | disclosed |
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176796-A1 | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | TP53, NFATC1, MAP3K15 | CCNA2 1338/4885CDK2 178/4885CCNA1 1187/4885 |
| US-20110034441-A1 | INDAZOLES AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | CCNA2 1285/4885CDK2 171/4885CCNA1 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.